"This work is significant because it shows that a SIRT1 activator can protect against neurodegeneration, highlighting the therapeutic potential of SIRT1 activators," said David Sinclair.
Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris Pharmaceuticals added "These new data support our belief in SIRT1 as a therapeutic target for neurodegenerative disease, which expands the potential of our pipeline of SIRT1 modulators designed to treat a number of diseases of aging such as metabolic and mitochondrial disorders, and now neurological disorders."
Online copies of the article can be obtained at: http://www.nature.com/emboj
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
concerning Sirtris Pharmaceuticals, its product candidates, and
those candidates' clinical potential. These forward-looking
statements about future expectations, plans and prospects of
Sirtris Pharmaceuticals involve significant risks, uncertainties
and assumptions, including risks related to the lack of results
that would provide a basis for predicting